News & Updates

Show Multimedia Only

NAFLD screening recommended in overweight, obese kids with T1D

06 Mar 2021

Nonalcoholic fatty liver disease (NAFLD) does not seem to occur at elevated rates among children and young adults with type 1 diabetes (T1D) but shows signals among those overweight or obese, reports a new study.

NAFLD screening recommended in overweight, obese kids with T1D

06 Mar 2021

Methylprednisolone + standard care may reduce HBV-ACLF–related mortality

05 Mar 2021 by

The addition of methylprednisolone to standard care* reduced mortality risk in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), according to a study from China.

Methylprednisolone + standard care may reduce HBV-ACLF–related mortality

05 Mar 2021

Modified Mediterranean diet halves NAFLD risk

26 Feb 2021 by

A modification of the Mediterranean diet (MED), otherwise called green-MED, may reduce the risk of developing NALFD*, the DIRECT PLUS** trial suggests.

Modified Mediterranean diet halves NAFLD risk

26 Feb 2021

Statins yield cancer survival gains in NAFLD patients

26 Feb 2021

Among patients with nonalcoholic fatty liver disease (NAFLD), use of statins considerably reduces cancer-related mortality, a study has found.

Statins yield cancer survival gains in NAFLD patients

26 Feb 2021

Unrestricted DAA use could reduce HCV incidence in HIV

25 Feb 2021 by

Unrestricted access to direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection in individuals with HIV led to a substantial reduction in HCV incidence, particularly in the key subgroup of men who have sex with men (MSM), according to a retrospective Dutch study.

Unrestricted DAA use could reduce HCV incidence in HIV

25 Feb 2021

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

24 Feb 2021 by

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not result in worsening renal function or bone mineral density (BMD) in Asian patients with chronic hepatitis B virus (HBV) infection, according to a small real-world prospective study.

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

24 Feb 2021

Cirrhosis tied to worse survival among COVID-19 patients

24 Feb 2021

Cirrhosis is associated with poorer survival among chronic liver disease (CLD) patients with the novel coronavirus disease (COVID-19), a recent study has found. Such association is more pronounced in those with more advanced cirrhosis or with alcohol-related liver diseases.

Cirrhosis tied to worse survival among COVID-19 patients

24 Feb 2021

Proton beam radiotherapy matches radiofrequency ablation in recurrent/residual HCC

23 Feb 2021

Proton beam radiotherapy (PBT) is a tolerable and safe approach to recurrent/residual hepatocellular carcinoma (rHCC) that yields comparable local progression-free survival (LPFS) rates to radiofrequency ablation (RFA), reports a recent study.

Proton beam radiotherapy matches radiofrequency ablation in recurrent/residual HCC

23 Feb 2021

Infigratinib emerges as potential treatment for advanced cholangiocarcinoma

16 Feb 2021 by

Infigratinib may be a suitable second- or later-line treatment option for patients with advanced or metastatic cholangiocarcinoma (CCA) with FGFR2* fusions or rearrangements, according to interim results of a phase II, open-label, single-arm study presented at ASCO GI 2021.

Infigratinib emerges as potential treatment for advanced cholangiocarcinoma

16 Feb 2021

Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world

02 Feb 2021 by

The combination of sofosbuvir plus velpatasvir does as well in the real world as in a Japanese phase III trial in hepatitis C virus (HCV) patients with decompensated cirrhosis, although there have been incidences of treatment discontinuation and liver disease-related death, as reported by a team of researchers.

Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world

02 Feb 2021

News & Updates

Filter by Specialty:

Specialty:

NAFLD screening recommended in overweight, obese kids with T1D

NAFLD screening recommended in overweight, obese kids with T1D

Methylprednisolone + standard care may reduce HBV-ACLF–related mortality

Methylprednisolone + standard care may reduce HBV-ACLF–related mortality

Modified Mediterranean diet halves NAFLD risk

Modified Mediterranean diet halves NAFLD risk

Statins yield cancer survival gains in NAFLD patients

Statins yield cancer survival gains in NAFLD patients

Unrestricted DAA use could reduce HCV incidence in HIV

Unrestricted DAA use could reduce HCV incidence in HIV

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

Cirrhosis tied to worse survival among COVID-19 patients

Cirrhosis tied to worse survival among COVID-19 patients

Proton beam radiotherapy matches radiofrequency ablation in recurrent/residual HCC

Proton beam radiotherapy matches radiofrequency ablation in recurrent/residual HCC

Infigratinib emerges as potential treatment for advanced cholangiocarcinoma

Infigratinib emerges as potential treatment for advanced cholangiocarcinoma

Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world

Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world